Responses
Other responses
Jump to comment:
- Published on: 13 June 2020
- Published on: 13 June 2020COVID-19 and immunosuppression in ophthalmic disorders
The review article by Thng ZX, De Smet MD, Lee CS, et al 1highlights the most intriguing aspects on use of immunosuppressants during and post COVID-19 pandemic. The authors have presented evidences based on various reports in a very well-structured manner and we would like to first thank and congratulate the authors for their work. The review covers the wide range of faculties of medicine where immune suppression is likely to be the main stay of treatment. At the same time, they have also very neatly presented with the “clear cut “ guidelines on the dosing of these various medications at different scenarios and patient status.
While the article additionally covers the following aspects very well ;
1) Does the use of immunosuppressive present as an independent risk factor for contracting COVID -19 in patients under them?
2) Does it affect the severity of COVID -19 ?We have few inquiries to make to the authors regarding the use of immunosuppressive in ophthalmology during this difficult time.
The authors have used the term “high dose steroids” in their article. Firstly, we are curious to understand what would be the considered the criteria to define a “high dosage” of steroid in ophthalmology. From our understanding, it depends upon the class of steroid used and the body weight2 but should we also need to consider the duration of use and cumulative dosage over a stretch of time to define it?
Also, referring to various public...
Show MoreConflict of Interest:
None declared.